The clinical value of the 99Tcm-MIBI scintigraphy in predicting the chemotherapy response of non-Hodgkin's lymphoma

WANG Jian; ZHU Xiang; XU Wengui; ZHOU Wen

doi:10.3874/j.issn.1674-1897.2015.03.L0302

Abstract：Objective To investigate the usefulness of 99Tcm-MIBI scintigraphy in assessing the chemotherapy response, predicting prognosis of non-Hodgkin's lymphoma. Methods Twenty patients underwent early (10 min) and delayed (120 min) 99Tcm-MIBI scintigraphy before and after chemotherapy. The early uptake rate (EUR), delay uptake rate (DUR), and washout rate (WR%) were calculated. Clinical response was assessed. The average follow-up time was 34 months. Results After chemotherapy, 8 patients showed complete remission (CR) with 99Tcm-MIBI negative and 12 patients had positive imaging. 4 of them presented partial remission (PR), 2 were in stable disease (SD) and 6 were in progressive disease (PD). Patients were divided into two groups, 12 in partial or complete response (CR+PR)and 8 in stable or progressive disease (SD+PD)group. There was statistically difference in DUR before and after chemotherapy in all the 20 patients (2.9 ±1.2 vs. 1.2 ±0.7, P＜0.05). Before chemotherapy,the DUR was significantly higher in partial or complete response group than that in stable or progressive disease group (2.9±1.2 vs. 1.5±0.9, P＜0.05). The WR% was significantly lower in partial or complete response group than that in stable or progressive disease group (21.9±2.4 vs. 42.7±50.6, P＜0.05). After chemotherapy the DUR was significantly lower in partial or complete response group than that in stable or progressive disease group (1.0±0.2 vs. 2.0±0.3, P＜0.05). Conclusion As a functional imaging, 99Tcm-MIBI scintigraphy is helpful in assessing the chemotherapy response andpredicting prognosis of non-Hodgkin's lymphoma.